Evaluation of non-invasive continuous physiological monitoring devices for neonates in Nairobi, Kenya: a research protocol by Ginsburg, Amy Sarah et al.
eCommons@AKU 
Paediatrics and Child Health, East Africa Medical College, East Africa 
3-2020 
Evaluation of non-invasive continuous physiological monitoring 
devices for neonates in Nairobi, Kenya: a research protocol 
Amy Sarah Ginsburg 
Evangelyn Nkwopara 
William Macharia 
Roseline Ochieng 
Mary Waiyego 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_paediatr_child_health 
 Part of the Pediatrics Commons 
Authors 
Amy Sarah Ginsburg, Evangelyn Nkwopara, William Macharia, Roseline Ochieng, Mary Waiyego, Guohai 
Zhou, Roman Karasik, Shuai Xu, and J Mark Ansermino 
1Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184
Open access 
Evaluation of non- invasive continuous 
physiological monitoring devices for 
neonates in Nairobi, Kenya: a 
research protocol
Amy Sarah Ginsburg   ,1 Evangelyn Nkwopara,2 William Macharia,3 
Roseline Ochieng,3 Mary Waiyego,4 Guohai Zhou,5 Roman Karasik,6 Shuai Xu,7,8 
J Mark Ansermino9
To cite: Ginsburg AS, 
Nkwopara E, Macharia W, et al.  
Evaluation of non- invasive 
continuous physiological 
monitoring devices for 
neonates in Nairobi, Kenya: a 
research protocol. BMJ Open 
2020;10:e035184. doi:10.1136/
bmjopen-2019-035184
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
035184).
Received 21 October 2019
Revised 10 March 2020
Accepted 23 March 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Amy Sarah Ginsburg;  
 messageforamy@ gmail. com
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
Strengths and limitations of this study
 ► This research consists of two phases, a verification 
and accuracy evaluation phase and a clinical fea-
sibility evaluation phase, and includes evaluation 
of two novel, investigational, non- invasive, mul-
tiparameter, continuous physiological monitoring 
devices.
 ► Verification of the reference devices is undertak-
en prior to initiating the accuracy evaluation of the 
investigational devices to ensure the reference de-
vices are robustly functional and to confirm their 
within subject repeatability and accuracy compare 
to standard clinical measurements for the relevant 
parameters of interest.
 ► Reliability information gathered from the reference 
devices is used to determine specific a priori Go/No 
Go criteria for each parameter of interest and each 
investigational device.
 ► As with all measurements, there is uncertainty in-
herent in the measurements from the reference 
devices.
 ► Inability to control for the characteristics and con-
ditions of the participating neonates and to stan-
dardise the environment and context are both 
strengths and limitations to interpreting the results.
AbStrACt
Introduction Continuous physiological monitoring devices 
are often not available for monitoring high- risk neonates 
in low- resource settings. Easy- to- use, non- invasive, 
multiparameter, continuous physiological monitoring 
devices could be instrumental in providing appropriate 
care and improving outcomes for high- risk neonates in 
these low- resource settings.
Methods and analysis The purpose of this prospective, 
observational, facility- based evaluation is to provide 
evidence to establish whether two existing non- invasive, 
multiparameter, continuous physiological monitoring 
devices developed by device developers, EarlySense and 
Sibel, can accurately and reliably measure vital signs 
in neonates (when compared with verified reference 
devices). We will also assess the feasibility, usability 
and acceptability of these devices for use in neonates in 
low- resource settings in Africa. Up to 500 neonates are 
enrolled in two phases: (1) a verification and accuracy 
evaluation phase at Aga Khan University—Nairobi and (2) 
a clinical feasibility evaluation phase at Pumwani Maternity 
Hospital in Nairobi, Kenya. Both quantitative and qualitative 
data are collected and analysed. Agreement between the 
investigational and reference devices is determined using 
a priori- defined accuracy thresholds.
Ethics and dissemination This trial was approved by the 
Aga Khan University Nairobi Research Ethics Committee 
and the Western Institutional Review Board. We plan to 
disseminate research results in peer- reviewed journals 
and international conferences.
trial registration number NCT03920761.
IntroduCtIon
In 2017 globally, 47% of all deaths in children 
under 5 years of age occurred within the first 
28 days of life, which translates to a neonatal 
mortality rate of 18 deaths per 1000 live births 
or 2.5 million newborn deaths.1Sub- Saharan 
Africa bears the greatest burden of neonatal 
mortality with an estimated 1 million newborn 
deaths in 2017. Further efforts, especially 
in African countries, are needed to push 
progress towards achieving the Sustainable 
Development Goal target of reducing global 
neonatal mortality to 12 deaths per 1000 
live births by 2030.2 Without accelerated 
improvements, it is projected that 1.8 million 
neonates will die in 2030.3 Innovations in 
neonatal care, particularly technologies that 
allow for early detection and intervention 
for major morbidities, hold great promise 
in helping to reduce current and projected 
neonatal mortality rates.
Multiparameter continuous physiological 
monitoring devices could be instrumental 
in identifying neonates at risk. We can then 
direct care provided for a neonate through 
automatic interpretations of vital signs that 
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Table 1 Eligibility criteria
Eligibility criteria
Inclusion criteria Male or female neonate, corrected age 
of <28 days
Willingness and ability of neonate’s 
caregiver to provide informed consent 
and to be available for follow- up for the 
planned duration of the study
Exclusion criteria Receiving mechanical ventilation or 
continuous positive airway pressure
Skin abnormalities in the nasopharynx 
and/or oropharynx
Contraindication to application of skin 
sensors
Known arrhythmia
Any medical or psychosocial condition 
or circumstance that, in the opinion of 
the investigators, would interfere with 
the conduct of the study or for which 
study participation might jeopardise the 
neonate’s health
help identify critical events and determine if treatment is 
sufficient or insufficient, ultimately improving newborn 
outcomes.4 5 These devices would be most useful in low- 
resource settings where the need for such technologies 
is greatest. While continuous physiological monitoring 
is standard of care in high- resource settings for those 
who require it, the devices are expensive and require 
specialised training to operate, making them unsuitable 
for application in low- resource settings. To address these 
barriers, it is necessary to explore how these technologies 
can be adapted and/or optimised for use in low- resource 
settings. Ideally, the devices should be low cost, operator- 
independent, non- invasive and highly efficient in diag-
nostic performance and operator workload. This requires 
development of a robust testing platform that appropri-
ately mimics conditions common in African newborn 
or neonatal intensive care units that would allow these 
type of technologies to be evaluated for feasibility and 
performance.
The Evaluation of Technologies for Neonates in Africa 
(ETNA) project was conceived with the goal of advancing 
and supporting development, as well as evaluation, of 
select devices for use in neonates in low- resource settings. 
By establishing a testing platform in an African site, 
and working collaboratively with partners with exper-
tise in device development and evaluation and neonatal 
and child health, the project seeks to boost develop-
ment and optimisation of promising newborn care 
devices that could be applied in low- resource settings 
in Africa.We acknowledge the many challenges involved 
in implementing such devices in low- resource settings 
(eg, electricity and internet access, behavioural change 
communication, etc), and the need to consider these 
challenges carefully prior to introduction.The purpose 
of this initial research is to produce evidence regarding 
the performance of two existing non- invasive, multipa-
rameter, continuous physiological monitoring devices 
developed by device developers, Early Sense and Sibel, 
to accurately and reliably measure vital signs in neonates 
(when compared with verified reference devices) and to 
assess the feasibility, usability and acceptability of these 
devices for use in neonates in a low- resource setting in 
Africa.
MEthodS And AnAlySIS
Study design and setting
The primary objectives of this prospective, observa-
tional, facility- based research are: (1) to assess agreement 
between repeat observations by the investigational device 
and the reference device for each relevant measure-
ment parameter of interest based on a priori- determined 
accuracy threshold among neonates; (2) to compare 
clinical event detection performance between the inves-
tigational device and the reference device and (3) to 
determine whether the investigational device is feasible, 
usable and acceptable to hospital administrators, health-
care providers and caregivers of neonates. Secondary 
objectives include: (1) assessing diagnostic performance 
for each relevant measurement parameter of interest 
based on sensitivity, specificity, positive predictive value 
and negative predictive value compared with the refer-
ence device; (2) determining the downtime performance 
of the investigational device; (3) determining the alarm 
rate (events/hour) and the number of true/false alarms 
of the investigational device compared with the reference 
device; (4) determining the delay time between the inves-
tigational device and the reference device in true events 
and (5) determining the number of adverse device effects 
(ADEs) and serious adverse events (SAEs) during the use 
of the investigational device.
Beginning in June 2019 and anticipated to last approxi-
mately 18 months in Nairobi, Kenya, this research consists 
of two phases: (1) a verification and accuracy evaluation 
phase conducted at Aga Khan University- Nairobi (AKU- 
N), a private, not- for- profit university teaching hospital 
with a neonatal intensive care and high dependency units 
and (2) a clinical feasibility evaluation phase conducted at 
Pumwani Maternity Hospital (PMH), the largest referral 
maternity hospital in sub- Saharan Africa with no neonatal 
intensive care or high dependency units.
Study participants
Up to 500 neonates, corrected age of <28 days admitted 
for routine observation and care at AKU- N and PMH are 
recruited by trained study staff during routine intake and 
screening procedures. To avoid potential selection bias, 
neonates are screened for enrolment in a sequential 
manner, as much as possible. Trained study staff assess the 
neonate for all inclusion and exclusion criteria (table 1). 
Final eligibility determination is dependent on the results 
of the medical history, clinical examination, appropriate 
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understanding of the study by the caregiver and comple-
tion of the written informed consent process. A neonate 
may be enrolled to the study more than once as long as 
they meet the eligibility criteria and the caregiver(s) is 
willing to have the neonate participate.
For the feasibility, usability and acceptability assessment, 
hospital administrators and study healthcare providers are 
enrolled if they are 18 years or older, involved in or aware 
of the ETNA study, and have provided written informed 
consent. Caregivers may be enrolled if they are 18 years 
or older, have a neonate enrolled in the study and are 
willing to participate in an in- depth interview as well as 
direct observation while their neonate is on or attached 
to the investigational device(s).
Investigational devices
Developed by Israeli- based EarlySense since 2009, the 
Insight system, released in 2016, is a contact- free moni-
toring system composed of a small piezoelectric sensor 
pad that can be placed under the patient’s mattress, and 
is designed to measure and record a patient’s heart rate 
(HR), respiratory rate (RR), motion and sleep status.6 
Information from the sensor pad, in combination with 
Early Sense’s artificial intelligence analytics, is transmitted 
to a monitor to provide alert indications and vital sign 
trends to healthcare providers so that they can monitor 
changes in a patient’s condition. Currently in use in 
hospitals, rehabilitative centres, and nursing homes to 
measure vital signs in adults and children above 10 kg, 
the device is modified for use in neonates as part of this 
study. The adult device received regulatory approval from 
the US Federal Drug Administration and has a Confor-
mité Européene mark for continuous and contactless 
measurement of HR, RR and motion. No adverse events 
(AEs) related to the system have been reported during 10 
years of monitoring.
Developed in 2019, the advanced neonatal epidermal 
(ANNE) system from Sibel, a technology company spun 
out from the Center of Bio- Integrated Electronics at 
Northwestern University in the USA, is a system of two 
time- linked soft and flexible sensors designed to measure 
and monitor vital signs including HR, RR, oxygen satura-
tion (SpO2) and skin temperature in neonates.
7 The chest 
sensor couples to the skin via a hypoallergenic, biocom-
patible hydrogel adhesive optimised for reduced peel 
force on removal, and the limb unit couples via a latex- 
free soft fabric wrap adaptable to a range of foot sizes 
and anatomies. Information from the sensors is wirelessly 
transmitted to a monitor or mobile device via encrypted 
Bluetooth for real- time streaming from a customised 
mobile software application as well as onboard memory 
storage on the sensors themselves. The device has been 
validated in more than 50 neonates in a neonatal care 
unit without AEs.
reference devices
We are employing the Masimo Rad-97 and the Spengler 
Tempo Easy Bleu devices as our reference devices for this 
study. The Masimo Rad-97 provides continuous physio-
logical monitoring of HR, RR, SpO2 and capnography. 
The Spengler Tempo Easy Bleu non- contact infrared 
thermometer predicts core body temperature from the 
temporal artery temperature.
Study procedures
Following completion of screening for eligibility, a study 
comprehension checklist and written informed consent, 
study staff perform procedures (online supplementary 
appendix 1: Schedule of study procedures and evalua-
tions) according to the most recently approved version 
of the protocol (current V.1.1, 18 June 2019). Enrolled 
neonates are assigned a participant identification 
number; information is collected on sociodemographic 
characteristics, current clinical status, medical history, 
medications; and a physical examination is performed.
Prior to initiating the accuracy evaluation of each inves-
tigational device, verification of the reference devices, 
Masimo Rad-97 and Tempo Easy Bleu, is undertaken 
at AKU- N to ensure they are robustly functional and to 
confirm their within subject repeatability and accuracy 
compared with standard clinical measurements (eg, 
manual, bedside electrocardiography) for the relevant 
parameters of interest. Neonates enrolled during refer-
ence device verification continue to receive local standard 
of care while being observed intermittently for vital signs 
collection for a minimum of 1 hour using the Masimo 
Rad-97 and intermittent measurements with the Tempo 
Easy Bleu. Observations may include video recordings 
of the neonate and the Masimo Rad-97 reference device 
monitor for later review to facilitate manual count obser-
vations. The reference device measurements will be 
compared with manual measurements, clinical monitor 
observations and video- assisted observations. Reliability 
information gathered from the reference devices is used 
to determine specific Go/No Go criteria for each param-
eter and each investigational device. Further evaluation 
of each investigational device only proceeds should these 
criteria be met.
Enrolment in the accuracy evaluation of the investiga-
tional devices, EarlySense Insight system and Sibel ANNE 
system, is initiated at AKU- N to formally assess their accu-
racy compared with the verified reference device using 
repeated observations. Enrolled neonates continue to 
receive local standard of care while having vital signs 
collected from the reference device as well as one or both 
of the investigational devices. Placement of the investiga-
tional and reference devices is done in a manner so as 
not to interfere with the neonate’s clinical care. Observa-
tions are collected for a minimum of 1 hour and poten-
tially for the entire duration of their stay in the hospital. 
Observations may consist of videotaping and/or taking 
photos of the neonate during the observation period 
after obtaining informed consent from the caregiver. Any 
photos or videos takes are identified by patient identifica-
tion number only and stored on a secure server until the 
analyses are completed and destroyed following analyses. 
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During the observation, clinical status and any activities 
are updated and recorded including type and duration 
of care activities (eg, feeding, diaper changes, bathing, 
kangaroo mother care, etc), clinical procedures, interven-
tions, therapies, laboratory tests, medications, environ-
mental features and exposures during the hospitalisation. 
The device placement, output and signal quality are also 
monitored. In addition, the neonates are assessed for any 
safety issues. Agreement between the investigational and 
reference devices is determined using a priori- defined 
accuracy thresholds. Thresholds are determined largely 
based on repeated within and between subject observa-
tions during verification of the reference devices. This 
is complemented by previously published international 
standards where available, and clinical expert consensus 
opinion as needed. Two a priori- determined thresholds 
are determined: one lower threshold to allow the device 
developer to optimise the device for retesting, and a 
second higher threshold to allow the device to move on 
to the clinical feasibility phase of testing. A maximum of 
five rounds of testing and retesting are permitted for each 
investigational device. Each round of testing or retesting 
consists of using a cohort of 20 neonates. Should the 
lower threshold not be reached for at least one param-
eter, no further testing of the investigational device is 
performed. Thus, information collected during the accu-
racy evaluation along with the a priori- determined Go/
No Go criteria established during verification of the refer-
ence devices define which, if any, of the investigational 
devices moves forward with additional rounds of testing 
or into the clinical feasibility evaluation phase at PMH.
An investigational device advances to the clinical 
feasibility evaluation phase once the agreement for the 
measurement parameters of interest exceed the higher 
accuracy threshold. Enrolment in the clinical feasibility 
evaluation phase of the investigational devices occurs at 
PMH up to 120 enrolled neonates who receive local stan-
dard of care while being monitored with the reference 
device(s)and one or both of the investigational devices. 
Observations are collected for a minimum of 1 hour and 
involve measurement of vital signs via the investigational 
and reference devices and monitoring for any critical 
event (ie, low or high HR, RR or temperature or oxygen 
desaturation and apnoea). Agreement between repeated 
observations from the investigation a land reference 
devices as well as diagnostic performance in clinical event 
detection is evaluated. Additional performance metrics 
such as alarm rates, alarm delays and uptime\downtime 
are compared between the investigational and reference 
devices. Participation in the study does not interfere with 
or unnecessarily delay the clinical care of the neonates.
Throughout all phases of the research, the investiga-
tional devices are not used to inform clinical care. During 
the clinical feasibility evaluation phase, ETNA site study 
staff and hospital healthcare providers are blinded to 
the data collected from the investigational devices to 
prevent interference with clinical care. The study site 
investigators are responsible for close safety monitoring 
of all participating neonates, including assessing for and 
reporting ADEs (eg, erythema or oedema at the investi-
gational or reference device sensor site) and/or SAEs (ie, 
any ADE resulting in permanent skin damage). Any ADEs 
or SAEs will be treated until resolution or stabilisation, 
and may require removal of devices and withdrawal of the 
neonate from the study if necessary. If withdrawn by the 
study team, any enrolled neonate who completes at least 
1 hour of monitoring will be included in the analysis and 
results.
Qualitative substudy
After written informed consent is received from the study 
participants, a mixed- methods evaluation and data collec-
tion through audio- recorded semistructured in- depth 
interviews and direct observations are conducted by 
trained qualitative study staff to assess the feasibility, 
usability and acceptability of the investigational devices 
for monitoring of neonates in an African setting. Ques-
tions around technology use, experience with continuous 
monitoring devices and specific to each investigational 
and reference device will be asked and their use observed. 
All hospital administrators and study healthcare providers 
may be involved in this portion of the study. Caregivers 
with a neonate enrolled in the study may also be asked if 
they would like to participate in the qualitative portion of 
the study.
Sample size
A total of up to 500 neonates are enrolled. For the veri-
fication of the reference devices at AKU- N, up to 30 
neonates are enrolled. Once this initial testing and data 
collection of the reference devices are complete, for the 
accuracy evaluation phase at AKU- N, up to 120 neonates 
per investigational device are enrolled. Sample size esti-
mates for the verification of the reference devices and the 
accuracy evaluation phase are based on the CIs desired 
for the limits of agreement. Sample sizes of 100–200 
typically provide tight CIs. A sample of 20 neonates with 
10 replications per neonate per device per round of 
testing provides limits of agreement with 95% CIs±0.24, 
calculated as 1.96*sqrt(3/ (20*10)), times the SD of the 
paired differences. The paired differences are from the 
reference device and manual measurements obtained 
during verification of the reference device, and from 
the reference device and investigational device measure-
ments obtained during the accuracy evaluation phase. 
For the clinical feasibility evaluation phase at PMH, up 
to 120 neonates per investigational device are enrolled. 
The sample sizes for each phase have been selected to 
maximise the amount of information collected within the 
confines of the available resources.
For the feasibility, usability and acceptability assessment, 
the total sample size includes all hospital administrators 
and study healthcare providers willing to participate and 
provide consent as well as up to 30 caregivers willing to 
participate and provide consent study at each site.
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box 1 Study endpoints
Primary endpoints
 ► Agreement of the relevant measurement parameters of interest be-
tween the investigational device and the reference device at each 
observation.
 ► Agreement of clinical event detection between the investigational 
device and the reference device at each observation.
 ► Feasibility, usability and acceptability of the investigational device 
among hospital administrators and healthcare providers.
 ► Acceptability of the investigational device among caregivers.
Secondary endpoints
 ► Diagnostic performance of the investigational deviceto appropriately 
identify the following critical events:
 – Low heart rate.
 – High heart rate.
 – Low respiratory rate.
 – High respiratory rate.
 – Oxygen desaturation.
 – Apnoea.
 – Low temperature.
 – High temperature.
 ► Downtime duration of the investigational device.
 ► Alarm rate (events/hour and ratio of false positives to missed critical 
events of the investigational device’salarms compared with the ref-
erence device’s alarms.
 ► Response time of the investigational device’s alarms compared with 
the reference device’s alarms for critical events
 ► Proportion of neonates with adverse device effects and serious ad-
verse events resulting in skin damage.
data collection and quality assurance
Quantitative study data are collected by clinical study 
staff using designated source documents as well as elec-
tronic or paper- based case report forms. Data are stored 
and managed by a database developed via Research Elec-
tronic Data Capture, a secure web application. Contin-
uous physiological data and event data are recorded from 
the investigational and reference devices at least once a 
second. All electronic data are collected wirelessly or via 
a wired connection from the investigational and refer-
ence devices to a study laptop using custom software 
applications. Qualitative study data are collected using 
paper- based forms and audio recordings, which are subse-
quently transcribed for analysis.
Clinical research data, including data collected from 
the investigational and reference devices, are maintained 
through a combination of secure electronic data manage-
ment system and physical files with restricted access to 
ensure confidentiality. Two distinct study databases are 
maintained separately: the primary study database and a 
database with participating neonate’s personally identifi-
able information. To ensure accuracy and completeness, 
data are routinely reviewed by the investigators through 
quality assurance reviews, audits and evaluation of the 
study safety and progress. Guideline for Good Clinical 
Practice (GCP)/ISO 14155 compliance is followed to 
ensure accurate, reliable and consistent data collection.
data management
Primary data management activities, which include 
deidentified investigational and reference device data 
transfer using end- to- end encryption with two- factor 
authentication, data entry and validation, data cleaning, 
database quality control and disaster recovery plans are 
undertaken at the study site and are overseen by the 
on- site data manager. Data review and analysis, oversight 
and preparation of final study database is performed by 
the investigators in collaboration with the study site. Data 
are maintained and stored securely in databases hosted at 
the study site throughout the study and for at least 5 years 
after study closure. All data management activities are 
in compliance with International Council on Harmoni-
sation (ICH) GCP E6, sponsor organisation and institu-
tional requirements for the protection of children and 
confidentiality of personal and health information.
outcomes
We hypothesise that the investigational device is accu-
rate and reliable compared with the reference device for 
each relevant measurement parameter of interest among 
neonates and is feasible, usable and acceptable for use in 
neonates in low- resource settings. The primary endpoint 
and secondary endpoints are detailed in box 1.
Statistical analyses
Every second of data is automatically graded as optimal, 
acceptable and unacceptable based on predefined rules 
for each device and each measurement parameter of 
interest according to the quality of the data for each 
measurement parameter of interest. The Masimo Rad-97 
provides a signal quality index that is used to determine 
data quality for HR and SpO2. A custom algorithm has 
been produced to determine the capnography signal 
quality index. Each of the investigational devices also 
provides a signal quality index. The quality thresholds 
are determined following verification of the reference 
devices. All comparisons are performed from observa-
tions between two devices (or a single device during verifi-
cation). At least 10 observations of 60 s of optimal quality 
data in each neonate, at least 5 min apart, are randomly 
selected for each measurement parameter of interest 
from the full recording. For the clinical feasibility evalua-
tion phase, accuracy comparisons use optimal or accept-
able data. At least 3 hours of recording to a maximum of 
12 hours are used for the performance metrics such as 
alarm rates, alarm delays and uptime\downtime.
The repeatability of the reference device parameter 
estimates initially is assessed with the intraclass correla-
tion coefficient (ICC). Additional training or standardi-
sation of procedures is performed to ensure at least good 
repeatability (ICC >0.7). This is followed by measuring 
agreement between the repeated reference observations 
and between the manual, clinical monitor and video- 
assisted methods and the reference observations using 
the methods described by Bland and Altman for repli-
cated observations.8 The agreement is reported as a mean 
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bias with 95% CIs and 95% limits of agreement. Graph-
ical representation of the data is assessed with agree-
ment plots, Clarke error grids and Polar plots to identify 
extreme outliers and significant data trends.
In the accuracy evaluation, the root mean square 
difference and ICC are calculated for each measurement 
parameter of interest to compare the multiple repeated 
observations between the investigational and reference 
devices. The agreement between each investigational 
device and reference device(s) is then calculated using 
the methods described by Bland and Altman for repli-
cated observations. The agreement is reported as a 
mean bias with 95% CIs and 95% limits of agreement. 
Graphical representation of the data is be assessed with 
agreement plots, Clarke error grids and Polar plots to 
identify extreme outliers, impact on clinical decisions, 
and significant data trends. An a priori- defined accuracy 
margin for agreement is used as a threshold value to 
allow for decisions regarding proceeding to additional 
testing.
In the clinical feasibility evaluation phase, agreement 
between each investigational device and reference 
device(s) is assessed as in the accuracy evaluation phase. 
Event detection rates, alarm rates, alarm delays and 
uptime/downtime are summarised with means, medians 
SD and IQRs as appropriate. Summaries of sensitivity, 
specificity, positive predictive values and negative predic-
tive values comparing each measurement parameter of 
interest in the investigational device(s) to the reference 
device(s) are produced. Comparisons of binary events are 
assessed using Cohen’s weighted Kappa and McNemar’s 
test. The non- inferiority of alarm rates, alarm delays and 
uptime/downtime are evaluated based on prespecified 
thresholds.
Qualitative data are collected through in- depth inter-
views and/or semistructured questionnaires and anal-
ysed to assess feasibility, usability and acceptability of the 
investigational devices among hospital administrators 
and healthcare providers, and acceptability among care-
givers of enrolled neonates. Questions that explore famil-
iarity, knowledge, perceptions, attitudes and behaviours 
regarding the devices are included. The qualitative data 
are in narrative format and the results are descriptive. 
The questionnaires are coded and analysed using a code-
book with identified themes, including feasibility of using 
each investigational device, barriers and facilitators to 
use, and perceived value. Qualitative data analysis soft-
ware is used to organise, code and analyse the qualitative 
data in an iterative process. The study team starts by iden-
tifying an initial set of codes and themes based on the 
categories from the interview guides. During the coding 
process, attention is paid to identifying emergent issues 
and themes that are added to the codebook and included 
in the analysis. Responses from the interviews are coded 
and discrepancies discussed and resolved for the final 
analysis and theme identification.
Ethics and dissemination
Ethical approvals and consent
The study is conducted in accordance with the ICHGCP 
and the Declaration of Helsinki 2008. The protocol and 
other relevant study documents study were approved by the 
Western Institutional Review Board 20 191 102 (Puyallup, 
Washington, USA), and the Aga Khan University Nairobi 
Research Ethics Committee 2019/REC-02 (v2)(Nairobi, 
Kenya). Written informed consent is obtained in the local 
language by trained study staff from all eligible neonate’s 
caregivers and for the qualitative substudy, from partici-
pating hospital administrators, healthcare providers and 
caregivers prior to enrolment. Potential participants will 
have adequate time to ask questions and a comprehen-
sion checklist will be administered to ensure participant 
understanding.
Possible risks
Caregivers may feel compelled to enrol in the study in 
order to receive care for their neonate within a research 
setting, which may be perceived as of a higher quality 
than the standard of care. In order to minimise the risk 
of coercion, during the informed consent process, study 
staff emphasise that the neonate will receive the required 
medical care whether enrolled in the study or not. 
Other potential risks to study participation may include 
those associated with the placement and attachment of 
the investigational and reference devices, and delayed 
medical management. Study staff are trained in the appro-
priate placement of investigational and reference devices’ 
sensors to minimise discomfort to the neonates as well as 
to avoid interference with any assessment, treatment or 
intervention necessary for clinical care. There is a poten-
tial risk of skin irritation with the ANNE sensor system 
and neonates will be closely monitored and treated for 
any AEs. Study staff are also trained in integrating study 
procedures with clinical care and to always prioritise clin-
ical care above study procedures. Extreme care is taken to 
ensure that no necessary treatment is delayed to accom-
modate study procedures.
dissemination
We plan to disseminate study results in peer- reviewed 
journals and international conferences, targeting those 
involved in the clinical care of neonates in low- resource 
settings as well as those who develop and advise on poli-
cies and guidelines in those settings.
Efforts towards rigorous protocol
Dedicated study staff trained in GCP, operation, use and 
maintenance of the investigational and reference devices, 
and study- specific procedures follow neonates enrolled in 
the trial to assure the protocol and standard operating 
procedures are followed and data are accurately collected.
Standardised study- specific training, supervision and 
oversight are undertaken to ensure quality, consistency 
and harmonised trial procedures and implementation. 
Regular monitoring is provided by the coinvestigators 
 o
n
 April 13, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035184 on 12 April 2020. Downloaded from 
7Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184
Open access
to assess compliance with human subjects and other 
research regulations and guidelines, adherence to the 
study protocol and procedures, and quality and accuracy 
of data collected.
limitations and bias
Limitations to this study and potential sources of bias 
include the sampling strategy, the uncertainty inherent 
in the measurements from the reference devices, the 
limited standardisation of time of day of recording and 
the inability to control the conditions and standardise the 
context. Because there is a large variation in the various 
ages, weights, sizes, disease states, clinical presentations, 
interventions received and conditions of the participating 
neonates, it is not possible to control for all these vari-
ables. Likewise, the environment cannot be controlled, 
does not allow for complete standardisation and may 
introduce additional sources of bias. These limitations 
may also be viewed as strengths.
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